An overview of the clinical efficacy of HFA-BDP in asthma

Respiratory Medicine

Volumn 94, Issue SUPPL. D, 2000, Pages

  Muir, J F ^a  

^a ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; CORTICOSTEROID; NORFLURANE; TECHNETIUM 99M;

AEROSOL; AIRFLOW; ARTICLE; ASTHMA; BREATH HOLDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; FORCED EXPIRATORY VOLUME; GEOMETRY; HUMAN; LONG TERM CARE; LUNG; METERED DOSE INHALER; MULTICENTER STUDY; OROPHARYNX; PARTICLE SIZE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYSTEM; SEAL; SUSPENSION;

EID: 0033797047     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0954-6111(00)90119-7     Document Type: Article

References (10)

1. Improved performance characteristics of CFC-free aerosol MDIs
2. Breath-actuated MDI delivers 60% airway deposition with a new CFC-free beclomethasone formulation
3. The current laboratory determination of 'respirable mass' is not clinically relevant
4. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metred dose inhalers
5. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone
6. Efficacy response of inhaled beclomethasone in asthma is proportional to dose and is improved by formulation with a new propellant
7. -1 BDP inhaled from MDI containing CFC
8. Improved quality of life in patients with asthma switched from chlorofluoro-carbon (CFC) to hydrofluoroalkane (HFA) beclomethasone dipropionate (BDP) extrafine aerosol
9. Long-term safety of beclomethasone dipriopionate extrafine aerosol (HFA-BDP)
10. Evaluation of impairment of health related quality of life in asthma: Development of a questionnaire for use in clinical trials